News Sentiment

CPRX sentiment intelligence

Catalyst Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 31.47 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+0.1% over one week, +0.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA

Market Reaction

Balanced read

56/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend active 0.4% over four weeks
Fair value 55.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 27
Neutral 29
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
TradingView 9
Stock Titan 5
ChartMill 4
simplywall.st 4
Sahm 3
Quartr 3
marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 23
Deals and strategy 12
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
TechStock² Direct company coverage

Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA

Angelini has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals (NASDAQ:CPRX), valuing the company at roughly 9 times its estimated 2026 EBITDA. Catalyst investors received $31.50 per share in cash, a price that, when adjusted for Catalyst's estimated $861 million

Tone
Positive 70/100
Event
Deals and strategy
Published
15 Jul 2026 14:32
Source
TechStock²
Stock Titan Direct company coverage

Nasdaq moves to delist Catalyst Pharmaceuticals (Nasdaq: CPRX) common stock

Nasdaq has initiated the process to delist Catalyst Pharmaceuticals' (CPRX) common stock from the Nasdaq Stock Market LLC, as indicated by a Form 25 notification filed under Section 12(b) of the Exchange Act. This action signifies that Nasdaq has followed its rules to remove the

Tone
Negative 18/100
Event
Market update
Published
15 Jul 2026 14:12
Source
Stock Titan
Sahm Direct company coverage

Catalyst Pharmaceuticals (CPRX) Could Be 60% Undervalued As Merger Approval Reshapes The Board

Catalyst Pharmaceuticals (CPRX) stockholders have approved a merger agreement, leading to the resignation of all current directors once the transaction is complete. The stock has seen significant gains, with a 90-day return of 20.16% and a 5-year return of 461.96%, partly due to

Tone
Positive 71/100
Event
Deals and strategy
Published
14 Jul 2026 15:12
Source
Sahm
www.marketscreener.com Direct company coverage

Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600 Health Care

Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) was removed from the S&P 600 Health Care sector index on July 14, 2026, as reported by S&P Capital IQ. The company is a biopharmaceutical firm focused on developing and commercializing medicines for rare diseases, including FIRDAPSE

Tone
Negative 29/100
Event
Market update
Published
14 Jul 2026 08:26
Source
www.marketscreener.com
Market source Direct company coverage

Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger

Catalyst Pharmaceuticals stockholders have approved the company's merger with Angelini Pharma, where Catalyst will become a wholly owned subsidiary of Angelini Pharma. The merger proposal passed with the required majority vote at a special meeting on July 8, 2026. While an adviso

Tone
Positive 74/100
Event
Deals and strategy
Published
11 Jul 2026 02:10
Source
Market source
Stock Titan Direct company coverage

Solaris Energy gets S&P SmallCap 600 spot as Catalyst exits

Solaris Energy Infrastructure (SEI) will be added to the S&P SmallCap 600 index on July 15, 2026, replacing Catalyst Pharmaceuticals (CPRX). Catalyst Pharmaceuticals is being removed from the index due to its acquisition by Angelini Pharma. This change impacts index funds and pro

Tone
Negative 29/100
Event
Deals and strategy
Published
10 Jul 2026 14:41
Source
Stock Titan
Pluang Direct company coverage

Solaris Energy replaces Catalyst Pharmaceuticals in S&P SmallCap 600 as acquisition nears completion

Solaris Energy Infrastructure Inc. is set to replace Catalyst Pharmaceuticals Inc. in the S&P SmallCap 600 index on July 15, 2026. This change is prompted by Angelini Pharma's impending acquisition of Catalyst Pharmaceuticals. The shuffle signifies shifts within the small-cap mar

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Jul 2026 22:12
Source
Pluang
Quartr Direct company coverage

Catalyst Pharmaceuticals (CPRX) Proxy filing Summary

A special meeting is scheduled for July 8, 2026, for Catalyst Pharmaceuticals (CPRX) shareholders to vote on a proposed merger with Angelini Pharma S.p.A. Shareholders will receive $31.50 per share in cash, representing a 21% premium to the unaffected closing share price. The boa

Tone
Positive 71/100
Event
Deals and strategy
Published
09 Jul 2026 05:12
Source
Quartr
Quartr Direct company coverage

Catalyst Pharmaceuticals (CPRX) Q1 2025 earnings summary

Catalyst Pharmaceuticals (CPRX) reported a strong Q1 2025, with net revenues increasing 43.6% year-over-year to $141.4 million, driven by FIRDAPSE and the successful launch of AGAMREE. Net income more than doubled to $56.7 million. The company reaffirmed its full-year 2025 revenu

Tone
Positive 86/100
Event
Earnings
Published
09 Jul 2026 04:42
Source
Quartr
Stock Titan Direct company coverage

Catalyst Pharmaceuticals (NASDAQ: CPRX) investors back Angelini Pharma merger deal

Catalyst Pharmaceuticals' stockholders have approved the merger agreement with Angelini Pharma, where Catalyst will become a wholly-owned subsidiary of Angelini. While the merger proposal received overwhelming support, a non-binding advisory proposal for merger-related executive

Tone
Positive 71/100
Event
Deals and strategy
Published
08 Jul 2026 21:40
Source
Stock Titan
Quartr Direct company coverage

Catalyst Pharmaceuticals (CPRX) EGM 2026 Summary

This article provides a summary of Catalyst Pharmaceuticals (CPRX) Extraordinary General Meeting (EGM) held on July 8, 2026. Key aspects covered include meeting procedures, board introductions, corporate governance, and confirmation of quorum. The summary also references other re

Tone
Positive 74/100
Event
Market update
Published
08 Jul 2026 18:40
Source
Quartr
Sahm Direct company coverage

Catalyst Pharmaceuticals (CPRX) Stock Looks Fairly Valued After Phase 1 Agamree Data

Catalyst Pharmaceuticals (CPRX) stock appears fairly valued following positive Phase 1 data for Agamree and progress with the Angelini Pharma acquisition. The stock's P/E ratio is currently in line with both the biotech sector average and its implied fair ratio, suggesting it is

Tone
Neutral 50/100
Event
Deals and strategy
Published
06 Jul 2026 13:12
Source
Sahm
TradingView Direct company coverage

CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data

Catalyst Pharmaceuticals (CPRX) reported positive Phase I results for Agamree, suggesting its potential for new indications beyond Duchenne muscular dystrophy (DMD). The study indicated that Agamree offers corticosteroid benefits with less immunosuppression compared to PTC Therap

Tone
Positive 74/100
Event
Earnings
Published
02 Jul 2026 13:10
Source
TradingView
Finviz Direct company coverage

CPRX - Catalyst Pharmaceuticals Inc Earnings

This article provides a detailed financial overview of Catalyst Pharmaceuticals Inc. (CPRX), including its latest stock performance, key financial metrics, earnings data, and insider/institutional ownership. It highlights the company's strong growth in sales and EPS over various

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 02:09
Source
Finviz
Market source Direct company coverage

Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®

Santhera Pharmaceuticals announced topline results from a Phase 1 clinical study of AGAMREE® conducted by its North American partner, Catalyst Pharmaceuticals. The study in healthy adult volunteers showed that AGAMREE® delivers glucocorticoid and anti-inflammatory activity with l

Tone
Positive 74/100
Event
Earnings
Published
01 Jul 2026 05:00
Source
Market source
Stock Titan Direct company coverage

Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression

Catalyst Pharmaceuticals announced positive topline results from a two-part Phase 1 study of vamorolone in healthy volunteers. The study demonstrated balanced corticosteroid activity with expected cortisol suppression and no significant immunosuppressive activity at clinical dose

Tone
Positive 72/100
Event
Earnings
Published
30 Jun 2026 21:18
Source
Stock Titan
GlobeNewswire Direct company coverage

Vamorolone Demonstrates On-Target Glucocorticoid Activity

Catalyst Pharmaceuticals, Inc. announced positive topline results from a Phase 1 clinical study of vamorolone in healthy adult volunteers. The study showed that vamorolone delivers on-target glucocorticoid and anti-inflammatory activity with expected cortisol suppression, but wit

Tone
Positive 74/100
Event
Earnings
Published
30 Jun 2026 12:10
Source
GlobeNewswire
Stock Titan Direct company coverage

Catalyst's rare-disease steroid showed immune activity without the usual suppression

Catalyst Pharmaceuticals announced positive topline results from a Phase 1 study of vamorolone in healthy adults, demonstrating on-target glucocorticoid activity with expected cortisol suppression and without significant immunosuppression at clinical doses. The study compared vam

Tone
Positive 77/100
Event
Earnings
Published
30 Jun 2026 10:39
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX

This article provides access to the "Price to earnings forward" financial data for Catalyst Pharmaceuticals, Inc. (CPRX) on the Nasdaq Stock Market. It's presented through the TradingView platform, which offers various financial tools and market data services. The content emphasi

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 10:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX

This article displays information regarding the enterprise value to revenue forward for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX). It provides a snapshot of the company's financial data on TradingView. The content is primarily a data point without extensive analytical text.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX

This article provides the "Price to sales forward" financial metric for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX). It is presented within a financial data platform from TradingView, which also lists other company information and market data services. The content itself seems

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 11:11
Source
TradingView
MarketBeat Direct company coverage

Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026

As of June 15, 2026, Catalyst Pharmaceuticals (CPRX) had 7.95 million shares sold short, representing 7.25% of its public float, marking a 2.91% decrease from the previous report. The short interest ratio is 5.5 days to cover. This data indicates a slight decrease in bearish sent

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 21:39
Source
MarketBeat
Simply Wall Street Direct company coverage

Catalyst Pharmaceuticals (CPRX) Gets Early FTC Clearance For Angelini Merger

Catalyst Pharmaceuticals (NasdaqCM:CPRX) has received early U.S. Federal Trade Commission clearance for its proposed merger with Angelini Pharma, accelerating the regulatory review process. This clearance addresses a major regulatory hurdle for the acquisition, which is still con

Tone
Neutral 50/100
Event
Deals and strategy
Published
25 Jun 2026 08:10
Source
Simply Wall Street
Business Wire Direct company coverage

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. The law firm is scrutinizing whether the offered price of $31.50 per share adequately values the company and if the sales process was fair

Tone
Negative 38/100
Event
Market update
Published
24 Jun 2026 18:39
Source
Business Wire